Lilly's donanemab slowed Alzheimer's disease progression in …
WEBINDIANAPOLIS, March 13, 2021 /PRNewswire/ -- Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM) expand on previously reported top-line data that found ...
Lilly.com | Eli Lilly and Company
WEBSep 13, 2024 · Press Releases. ALL CORPORATE FINANCIAL PRODUCT IMPACT ARCHIVE. New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis. September 25, 2024.
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEB5 days ago · "Lilly scientists have been dedicated to research in Alzheimer's disease for more than 35 years, and this news is testament to their ingenuity, perseverance, and commitment to helping people with this disease," said Ilya Yuffa, executive vice president and president of Lilly International, Eli Lilly and Company.
All News - Eli Lilly and Company
WEBRecent Press Releases. View All Press Releases. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Lilly expands manufacturing footprint in Ireland with $1.8 billion investment.
News Release - Eli Lilly and Company
WEBSep 4, 2024 · Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa. INDIANAPOLIS and CAIRO, Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand access to ...
Eli Lilly’s stock soars toward best day in 23 years after strong ...
WEBAug 8, 2023 · Eli Lilly's stock soared Tuesday toward its biggest gain in more than 20 years, following a strong earnings report and upbeat outlook for its Mounjaro drug.
Alzheimer's drug donanemab shows positive results, Eli Lilly
WEBJul 17, 2023 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease
WEBMay 3, 2023 · The F.D.A. approved a new drug for early Alzheimer’s, the latest in a novel class of treatments that has been greeted with hope, disappointment and skepticism. A study suggests that genetics...
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth
WEBApr 30, 2024 · Eli Lilly (LLY) stock gained 6% Tuesday after the drugmaker reported first-quarter earnings that beat analysts' expectations and raised its guidance thanks to continued high demand for the...
Skip to content